Skip to Content

Posts tagged with "Cancer"

  • Business and Markets


    The real news on the cancer front is in the post below, but I have a few other things to take care of tonight, too. Yesterday’s post on Imclone’s stock price was not well-received over on the IMCL message boards on Yahoo, where I’ve picked up several of the usual responses. They include the standard-issue… Read More
  • Business and Markets

    Foaming Up Over the Edge

    It’s been a wild time recently in the oncology field – well, not so much scientifically as financially. OSI took a huge leap the other day on good clinical news about Tarceva, the drug they’re developing with Genentech. I’ll gloss over the fact that I owned OSI stock at one point, and sold it in… Read More
  • Biological News

    A New Cancer Target – Maybe

    In my industry, you hear a lot of talk about drug targets and their relative chances of success. Targets fall into several broad classes, and when you take a close look, there are clearly some that are easier to hit than others. The G-protein coupled receptors (GPCRs) are one of those (antihistamines and beta-blockers are… Read More
  • Alzheimer's Disease

    Back on the Air

    After a (reasonably) refreshing holiday break, Lagniappe is back. Thanks to everyone who kept doggedly hitting this site during the last few days – I admire your persistance. I notice from my site’s counter that I get a small but steady flow of Google hits for various miracle cures. I said some nasty things about… Read More
  • Cancer

    Pneumonia, of All Things

    There seems to be something odd going on with Iressa, AstraZeneca’s great oncology hope. In Japan (the only place where it’s on the market,) there’s been an unusually high incidence of interstitial pneumonia among its patients. The FDA has scheduled a December meeting, almost certainly to talk about this situation and how it affec… Read More
  • Business and Markets

    O Brave New Market, That Has Such Medicines In It

    I mentioned that Amgen had a rough time with their leptin program, but there are people who benefit tremendously from the protein. There are some people (very few, actually) who are similar to the ob/ob mouse, in that they have a mutation in their leptin protein gene. They tend to have a lot of metabolic… Read More
  • Cancer

    Not Even Funny

    I’m late to this particular party – see Charles Murtaugh and Medpundit for the low-down on a particularly irritating LA Times column. (It requires registration to read, which is fairly irritating all by itself.) In a nutshell, the writer attempts to blame environmental factors for many cases of breast cancer, specifically chemicals prod… Read More
  • Cancer

    Genetic Optimism

    he genetic news of the day, subject of good-sized headlines in the Wall St. Journal and elsewhere, is an upcoming paper in PNAS on a candidate cancer gene called DBC2. Some of these abbreviations are pretty recondite, but not this one – it stands for “Deleted in Breast Cancer,” which is pretty tame by the… Read More
  • Cancer

    The Wall Street Journal versus the FDA

    Here we are again. Back in February (see the Feb. 27th post), the FDA asked for more data for Imclone’s cancer therapy, Erbitux, saying the existing studies were not sufficient to approve the drug. The Wall Street Journal’s editorial page threw a memorable fit about what they saw as the FDA’s intransigence (to which piece… Read More
  • Cancer

    Consequences of Aneuploidy

    Man, with headlines like that, I can’t think of why I’m not pulling in thousands of hits a day. Anyway, I wanted to follow up on yesterday’s posting by emphasizing that aneuploidy hasn’t been ignored for all these years. It’s just that the chicken-and-egg question about its role in cancer is heating up. For example… Read More